About Us

Our team has developed breakthrough technologies that deliver advanced NGS-based genomic methods for research customers.

Frederick Jiang
Founder & President

Frederick Jiang, CFA is Co-Founder and Managing Partner of Plaisance Capital Management LLC, a venture capital investment company based in Boston and New York. Mr. Jiang brings to AccuraDX 24 years of capital market and management experiences gained through his investment and entrepreneurial career. Before co-founding Plaisance, Mr. Jiang was Co-Founder and Managing Partner of Coalescence Partners, an investment shop managing hedge fund and private equity fund in Boston and New York. Before that, Mr. Jiang was a Senior Vice President of Waddell & Reed / Ivy Funds, which was one of the oldest investment firms with a history of over 80 years. Mr. Jiang joined Waddell & Reed / Ivy Funds in 1999 as Asian Pacific Equity Analyst. He was named Portfolio Manager of Ivy Pacific Opportunities Fund in early 2003 and won Lipper Best Fund Awards for 3-years and 5-years performance in 2010. From 2013 and 2016 Mr. Jiang managed Ivy Emerging Market Equity Fund, a Lipper and Morningstar 5-star fund as of 3/31/2016. Before Waddell & Reed, Mr. Jiang was an equity research analyst for ABN Amro Asia between 1994 and 1997, covering Chinese equity market in Hong Kong and Shenzhen. Mr. Jiang graduated from China's Central University of Finance and Economics with a BA degree in Economics and Accountancy. Mr. Jiang received his MBA degree from Stern School of Business of New York University in 1999, and Certified Financial Analyst (CFA) charter in 2001.Through his 24 years of investment career, Mr. Jiang has invested in many biotech, medical device and pharmaceutical companies globally, including Elixell Therapeutics, Celltrion Healthcare, HebeCell, Sun Pharma, Applied StemCell, Lifetech Scientific, MitrAssist Ltd, among others.


Chuan He

Scientific Founder

Chuan He, Ph.D., is the John T. Wilson Distinguished Service Professor in the Department of Chemistry, Department of Biochemistry and Molecule Biology, and Institute for Biophysical Dynamics at the University of Chicago. Dr. He is also an Investigator of the Howard Hughes Medical Institute. Professor He graduated with a B.S. degree from the University of Science and Technology of China in 1994. He received his Ph. D. degree from Massachusetts Institute of Technology in chemistry in 2000 with Professor Stephen J. Lippard. After being trained as a Damon-Runyon postdoctoral fellow with Professor Gregory L. Verdine at Harvard University from 2000-2002, he joined the University of Chicago in 2002. Professor He also served as the director of Institute for Biophysical Dynamics from 2012-2017. Dr. He’s research spans a broad range of chemical biology, molecular biology, biochemistry, epigenetics, cell biology, and genomics. His recent research concerns reversible RNA and DNA methylation in biological regulation. His laboratory made the original discovery of reversible RNA methylation in 2011. His subsequent work demonstrated that dynamic RNA chemical modification represents a new mechanism for gene expression regulation. Professor He also invented widely utilized methods for mapping DNA epigenetic modifications and for applications in precision medicine. Dr. He is the director of the NIH National Human Genome Research Institute (NHGRI) Centers of Excellence in Genomic Science (CEGS), Center for Dynamic RNA Epitranscriptomes.


Ye Fu
Vice President  |  Research & Development

Dr. Ye Fu obtained a B.S. in Chemistry from Peking University in China, and a Ph.D. in Chemistry from the University of Chicago in Professor Chuan He's lab. Dr. Fu pioneered the work on dynamic regulation of RNA modifications and co-discovered the function of FTO as the first RNA m6A demethylase in 2011—a landmark in the field of epitranscriptomics. In addition, he developed high-throughput sequencing methods to map the genome-wide distribution of several base modifications—including 6mA and 5hmC in the eukaryotic genomes—and revealed their functions in regulating gene expression. Dr. Fu then completed postdoctoral research in the lab of Xiaowei Zhuang at Harvard University, where he used quantitative imaging and super-resolution imaging to study the function of RNA m6A-binding proteins in regulating the phase-separation of stress granules in mammalian cells. Dr. Fu has published more than 25 peer-reviewed publications, including first author articles in the journal Cell, Nature Chemical Biology, Nature Communications, Angewandte Chemie, as well as Nature Reviews Genetics. His work has been cited more than 10,000 times. Dr. Fu joins AccuraDX as the Vice President of Research and Development, and is working on advancing KAS-seq technologies to both basic science and translational applications.


Diana West-Szymanski

Vice President  |  Operations

Originally from Northern Virginia, Dr. West-Szymanski obtained a B.S. in chemistry at The College of William & Mary. She then obtained Ph.D. in chemistry at the University of Illinois at Urbana-Champaign, where she performed drug discovery and pre-clinical research on an anti-cancer compound now in clinical trials. After graduate studies, Dr. West-Szymanski completed postdoctoral research in breast and prostate cancer biology at The University of Chicago, followed by a teaching faculty position in chemistry and biochemistry at Ave Maria University, a small liberal arts college. In 2018, she returned basic research at The University of Chicago as a Staff Scientist jointly mentored by Professors Chuan He and Marc Bissonnette. In 2019, she was named as one of Halo's top 40 under 40 Chicago Scientists. Dr. West-Szymanski joined the team at AccuraDX as Product Development Lead when the company was founded in February 2020. Now as VP of Operations, she and is enthusiastic about getting exciting technologies into the hands of researchers.


Lu Gao

Business Development Consultant

Dr. Lu Gao serves the AccuraDX team as a business development consultant since Nov 2020. She is also a researcher in Cancer Early Detection jointly mentored by Professors Chuan He and Marc Bissonnette at The University of Chicago. Dr. Gao has over twelve years of experience in life science research. She obtained Ph.D. in Biochemistry and Molecular Biology at the University of Rochester, where she researched strand transfer events during HIV-1 reverse transcription. Additionally, after completing her MBA degree at the University of Iowa Tipple School of Business, she worked as an investment analyst for over two years with Principal Global Investors. She was also an entrepreneur and served as the owner and manager of Huntington Learning Center of West Des Moines in Iowa for two years. The combination of scientific and business backgrounds positions Dr. Gao to provide assistance with business operations and scientific-technical advice.


We are a University of Chicago spin-out company headquartered in Natick, MA with labs in Natick, MA and Chicago, IL.